9. Tysabri (Natalizumab)
Natalizumab (manufactured by Biogen Idec as Tysabri; previously named Antegren) is a humanized monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) as a monotherapy for the treatment of relapsing-remitting forms of multiple sclerosis (MS) and Crohn’s disease. Administered as an intravenous injection, the drug is believed to reduce or inhibit the ability of immune cells to invade the blood-brain barrier, protecting against autoimmune attacks by the body’s innate immune system to slow the worsening of symptoms and number of disease flares.
Tysabri is also approved as a disease-modifying monotherapy in the European Union (since 2006) for relapsing MS patients with high disease activity (two or more lesions in one year) despite treatment with a β-interferon or glatiramer acetate, and for those with rapidly evolving severe RRMS.
Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?